

#### For immediate release

25 June 2020

### TERRAGEN STRENGTHENS BOARD AND MANAGEMENT TEAM

# **Key points:**

- The Company appoints Mr Jim Cooper as Chief Executive Officer and Managing Director
- The Company continues to achieve strong sales growth over prior comparative periods

Terragen Holdings Limited ("Terragen") (ASX:TGH) today announces changes to the Board and executive roles as the Company transitions from research and development to growing sales of its products.

Chairman Dr Paul Schober said: "We are pleased to announce the appointment of Mr Jim Cooper as Terragen's new CEO. Jim brings to the team extensive commercial and operational experience and has impressed the Board since joining Terragen earlier this year. We are confident Jim will be an outstanding leader of the Company".

Mr Cooper was previously a senior executive at Port of Melbourne and prior to this, CEO at the Port of Portland.

As incoming CEO, Mr Cooper will take a seat on the Board as Managing Director, replacing Mr Justus Homburg.

Mr Homburg, who took Terragen to and through its December 2019 IPO, will continue to work closely with the Company as a consultant, focusing his efforts on strategy and product development. Mr Homburg will retain his options in the Company, the details of which are contained in the Form 3Z, filed with the ASX.

Terragen continues to achieve strong sales growth over prior comparative periods. The Company intends to provide shareholders an update on the continued implementation of its commercialisation and development strategy following the end of the financial year.

# **About Terragen Holdings Limited**

Terragen develops and markets a portfolio of biological products that use live microbes to address soil health and help boost the growth, productivity, welfare and resilience of farm production animals. The Company's aim is to increase farm productivity through the use of these products.

Terragen considers that its biological products will help generate better outcomes for farmers, and their crops and animals and will provide improved environmental outcomes that will be more acceptable to consumers.

Terragen has two products on the market in Australia and New Zealand: a microbial feed supplement 'Mylo®' for animals; and a microbial soil conditioner 'Great Land®'. Terragen is also developing veterinary medicines: Lactolin, a teat conditioner to maintain and improve the udders of lactating production animals, and Halo, an anti-inflammatory product to assist dairy cattle with mastitis and companion animals such as dogs with mobility impairments.

### For further information, please contact:

Terragen Holdings Limited	Authorisation & Additional information:
Paul Schober	This announcement was authorised by Dr
Chairman	Paul Schober, the Chairman of Terragen
media@terragen.com.au	Holdings Limited.
Jim Cooper	
CEO	
+ 61 417 321 145	
<u>jimc@terragen.com.au</u>	

### **ATTACHMENT**

### SUMMARY OF TERMS OF MR JIM COOPER'S APPOINTMENT

The key terms of Mr Cooper's appointment as Non-Executive Director are:

- i. **Role**: Chief Executive Officer.
- ii. **Appointment date**: 25 June 2020.
- iii. **Term**: No fixed term.
- iv. **Termination**: By resignation of Mr Cooper or removal from office as a Director in accordance with the Company's constitution or Part 2D.3 of the Corporations Act 2001 (Cth).
- v. **Remuneration**: Mr Cooper shall be entitled to the following under his Executive Services Agreement:
  - (a) \$301,125 salary per annum including superannuation; and
  - **(b)** provision of a company motor vehicle.
- vi. **Incentives**: Mr Cooper shall be entitled to participate in the Terragen Employee Incentive Plan subject to the usual Board and Shareholder approvals.